Where I see patients (1)
Selected research
-
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.
Blood advances
-
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.
Blood
-
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
Blood cancer discovery
Contact me
- Request appointment
- Refer a patient
- (415) 353-2421